Drug Update · Pulmonology

Smoking Cessation: FDA-Recognized NRT, Varenicline, and Bupropion Options

September 03, 2026

NRT OTC approved age

age 18 and older

FDA non-nicotine products

Varenicline tartrate; Bupropion hydrochloride

FDA NRT guidance

Final guidance May 2023 (Docket FDA-2019-D-0297)

Clinical Perspective

This affects clinicians who prescribe smoking-cessation pharmacotherapy and adult patients seeking to quit, because FDA consumer information lists over-the-counter NRT and prescription non‑nicotine tablet products as regulatory-recognized options for smoking cessation ^[2]. The FDA materials support offering NRT (patches, gum, lozenges, and prescription nicotine spray or inhaler) and prescription varenicline tartrate or bupropion hydrochloride as regulatory-recognized cessation options, and the FDA has provided development guidance for NRT products ^[2]^[3]. Comparative efficacy, head-to-head trial outcomes, detailed dosing, and comprehensive safety trade-offs between cytisinicline, varenicline, NRT, and bupropion are not reported in the provided source excerpts?

Dr. Nikhil Chatterjee, MBBS, MD (Respiratory Medicine) · Pulmonology

This Drug Update summarizes FDA-reviewed smoking cessation pharmacotherapies described in FDA consumer information and regulatory guidance, and notes absent source data for cytisinicline in the provided excerpts. FDA materials list over-the-counter nicotine replacement therapies (NRTs) and prescription non‑nicotine tablet products as regulatory-recognized cessation options, and the FDA issued final guidance for developing NRT products in May 2023 ^[2]^[3].

Clinical Context

Nicotine replacement therapy (NRT) is described by the FDA as providing the body with smaller doses of nicotine over time without exposing users to the toxic chemicals in cigarette smoke; NRT is intended to be used in conjunction with a behavioral program and has been found to increase the success of smoking cessation ^[2]. Over-the-counter NRTs approved for sale to people age 18 and older include skin patches, chewing gum, and lozenges, while prescription nicotine products include nicotine spray and nicotine inhaler ^[2]. The FDA consumer material also lists two FDA-approved, non-nicotine, prescription tablet products for smoking cessation: varenicline tartrate and bupropion hydrochloride, and states the FDA evaluated these drugs and found that the benefits outweigh the risks ^[2]. The FDA finalized guidance for developing NRT drug products in May 2023 (Docket FDA-2019-D-0297) to assist sponsors in clinical development for smoking cessation and related indications ^[3]. Cytisinicline is not reported in the provided source excerpts.

Key Findings

Nicotine replacement therapies have been found to increase the success of smoking cessation and “can even double your chance of quitting successfully,” according to the FDA consumer update describing FDA-approved and FDA-cleared cessation products ^[2].
Over-the-counter NRT forms approved for sale to people age 18 and older include skin patches (transdermal), nicotine gum, and nicotine lozenges ^[2].
Prescription nicotine-containing cessation products described by the FDA include nicotine spray and nicotine inhaler ^[2].
Two FDA‑approved smoking cessation products that do not contain nicotine are varenicline tartrate and bupropion hydrochloride, both available in tablet form by prescription only; the FDA states it evaluated these drugs and concluded that the benefits outweigh the risks ^[2].
The FDA issued a final guidance document in May 2023 titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products” (Docket FDA-2019-D-0297) to assist clinical development of NRT drug products ^[3].

Safety & Tolerability

Safety information was not available in the provided source excerpts.

Study Design

Specific randomized trials, comparative head-to-head study designs, primary endpoints, enrollment numbers, follow-up durations, and dosing regimens for cytisinicline, varenicline, NRT, or bupropion were not available in the provided source excerpts. The regulatory documents referenced in these excerpts are the FDA consumer update summarizing FDA‑approved and FDA‑cleared cessation products and the FDA final guidance “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products” (Docket FDA-2019-D-0297) issued May 2023 ^[2]^[3]. Additional entries on the FDA Novel Drug Approvals page were listed as content current as of 08/28/2026 but did not provide trial-level cessation data in the provided excerpts ^[1].

FAQ

Q1 What is the drug approved for?

The FDA consumer information and regulatory materials summarized in the provided excerpts describe FDA‑approved and FDA‑cleared smoking cessation products for adults, including over-the-counter nicotine replacement therapies (patches, gum, lozenges) approved for people age 18 and older and prescription nicotine spray and inhaler formulations. The excerpts also identify two FDA‑approved, non‑nicotine prescription tablet products for smoking cessation: varenicline tartrate and bupropion hydrochloride. Cytisinicline is not reported in the provided source excerpts.

Q2 How does it work?

According to the FDA consumer summary, nicotine replacement therapy helps people quit smoking by gradually providing the body with smaller doses of nicotine over time without exposing users to the toxic chemicals found in cigarette smoke; NRT is intended to be used in conjunction with a behavioral program. The provided excerpts note that varenicline tartrate and bupropion hydrochloride are FDA‑approved non‑nicotine prescription tablet products, but mechanistic details beyond those FDA statements were not available in the provided source excerpts.

Q3 What is the dose?

Dosing information for specific products, including exact regimens for nicotine replacement therapy forms, varenicline tartrate, bupropion hydrochloride, or cytisinicline, was not available in the provided source excerpts. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the side effects?

Detailed safety profiles, lists of adverse events, and comparative tolerability data for NRT products, varenicline tartrate, bupropion hydrochloride, or cytisinicline were not provided in the source excerpts. The FDA consumer page states the FDA evaluated the benefits versus risks for varenicline and bupropion, but the specific adverse events and their frequencies were not available in the provided excerpts.

Clinicians should consult current prescribing information for full dosing guidance.

Smoking Cessation: FDA-Recognized NRT, Varenicline, and Bupropion Options

Direct Clinical Takeaway & Evidence Summary

Smoking Cessation: FDA-Recognized NRT, Varenicline, and Bupropion Options

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Pulmonology in your inbox.

Related Clinical Updates

Trimbow, Trelegy, Breztri: triple-inhaler dosing and label differences for asthma

FDA Approves Trimbow for Asthma: Trough FEV1 Gains 57–73 mL

FDA Approves Trimbow for Maintenance Treatment of Asthma

Verified HCP Portal